Perspective Therapeutics gets FDA Fast Track for [212Pb]PSV359
Perspective Therapeutics said the U.S. Food and Drug Administration granted Fast Track designation for [212Pb]PSV359 to treat adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors.